Spotlight On: Neulasta® (Pegfilgrastim) / Fulphila® (Pegfilgrastim-Jmdb) / Udenyca® (Pegfilgrastim-Cbqv) / Ziextenzo® (Pegfilgrastim-Bmez) / Nyvepria®(pegfilgrastim-Apgf) / Fylnetra™ (Pegfilgrastim-Apgf) / Stimufend® (Pegfilgrastim-Fpgk) / Armlupeg™ (Pegfilgrastim-Unne) - April 2026

Why It Matters

Accurate claim counting shapes the perceived strength of pegfilgrastim patents, influencing biosimilar entry strategies and investor risk assessments in a highly contested oncology market.

Key Takeaways

• Claims counted per litigation/IPR, leading to multiple tallies per patent
• Within a single case, each claim counted only once
• Both §102 (novelty) and §103 (non‑obviousness) challenges included
• Methodology impacts perceived patent strength for pegfilgrastim biosimilars

Pulse Analysis

Pegfilgrastim, a growth factor used to prevent chemotherapy‑induced neutropenia, has become a focal point for biosimilar competition. Major players such as Neulasta and its newer biosimilars—Fulphila, Udenyca, Ziextenzo, Nyvepria, Fylnetra, Stimufend, and Armlupeg—navigate a dense web of patents covering formulation, delivery, and manufacturing processes. The high therapeutic value and sizable market, estimated at several billion dollars annually, attract aggressive patent enforcement, making the counting of challenged claims a critical metric for stakeholders assessing litigation exposure.

The article’s methodology distinguishes between claim duplication across separate proceedings and singular counting within each case. When a patent is contested in multiple IPRs or lawsuits, each instance adds to the total claim count, potentially inflating the apparent breadth of challenges. Conversely, within any given litigation or IPR, a claim is recorded only once, even if it faces both novelty (§102) and non‑obviousness (§103) attacks. This nuanced approach prevents double‑counting within a single forum while acknowledging the cumulative pressure a patent faces across the legal landscape.

For pharmaceutical companies and investors, this counting framework informs strategic decisions about biosimilar launch timing, settlement negotiations, and portfolio valuation. A higher aggregate claim count signals robust opposition, possibly delaying market entry and increasing development costs. Conversely, a clearer picture of claim distribution can guide targeted licensing or design‑around strategies, ultimately shaping the competitive dynamics of the pegfilgrastim market. Understanding these metrics is essential for navigating the complex interplay of patent law and oncology drug commercialization.